实力印证!复宏汉霖荣膺2025年度创新药企TOP10及中国医药创新企业100强第一梯队

复宏汉霖
Nov 28

近日,复宏汉霖(2696.HK)在医药行业两大权威评选中连获殊荣,彰显了公司在中国生物创新药领域的卓越实力与领先地位。在华夏时报社主办的第五届华夏大健康产业发展大会上,复宏汉霖喜获双重殊荣:公司荣登“2025年度创新药企TOP10”榜单,董事会秘书兼公众传播总经理王燕女士荣获“2025年度华夏大健康十大金牌董秘”称号;同期,在第十七届中国医药企业家科学家投资家大会(2025启思会)上,公司连续...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10